A 48-year-old male was admitted to our hospital due to a palpable mass in the right upper abdomen. The patient weighed 60 kg with a height of 178 cm, and the SLV was 1217 mL. Laboratory examination ( Table 2 ) revealed TBil 12.2 mumol/L, DBil 5.8 mumol/L, alkaline phosphatase (ALP) 1016 U/L, gamma gamma-glutamyl transpeptidase (gamma-GGT) 671 U/L, HBV-DNA 735780 IU/L, and HBsAg (+). AFP was at the normal level. Abdominal enhanced CT showed a 16.2 cm x 11.2 cm mass situated in the right liver with inhomogeneous enhancement of the mass in the arterial phase and multiple intrahepatic metastatic lesions ( Figure 2A ). In addition, the patient was administered interferon therapy when diagnosed with HBV. According to the BCLC-B stage, stereotactic therapy for HCC was performed (i.e., TACE combined with 8 mg lenvatinib once a day and 200 mg camrelizumab every three weeks,  Figure 2F ). Abdominal CT showed that the diameter of the lesion was reduced from 16.2 cm to 9.7 cm ( Figure 2B ) after three courses of TACE and ten cycles of camrelizumab. LFT was almost normal, except ALP 261 U/L and gamma-GGT 120 U/L. The first stage of ALPPS was performed with laparoscopy after obtaining the consent of the patient and his family. LFT suggested TBil 12.5 mumol/L, DBil 5.6 mumol/L, and ALT 163 U/L on the first day after surgery. One month after the first-stage surgery, the volume of FLR was 473 mL, which was more hypertrophic than the baseline volume of FLR (356 mL) ( Figure 2C ). The rate of FLR/SLV was 38.9%, and the patient received right hepatectomy plus right caudate-leaf resection by laparotomy. Changes in liver function are shown in  Figure 2E . The pathology report suggested moderately differentiated hepatocellular carcinoma with satellite nodules. Systemic therapy was restored one week after second-stage ALPPS. Re-examination of CT one month after second-stage ALPPS indicated sufficient FLR ( Figure 2D ).